Salivary Cancer clinical trials at University of California Health
1 research study open to eligible people
open to eligible people ages 18 years and up
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
Our lead scientists for Salivary Cancer research studies include Emily Bergsland.